A Phase 2 interventional study of Doravirine and 2 NRTIs in Human Immunodeficiency Virus (HIV) Infection, sponsored by Merck Sharp & Dohme LLC. Recruiting at 26 sites in 8 countries. Open to participants aged 4 Weeks to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The primary objectives are:
Participants who complete the Week 96 visit will be eligible to enroll in an Extension Study and receive DOR until it is commercially available, or for up to an additional 224 weeks (whichever comes first).
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
This study's planned enrollment of 84 is below the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study Extension Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive doravirine (DOR) at 7.2 mg to 100 mg, based on weight, PLUS 2 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs), based on local label, for 96 weeks, OR a fixed-dose combination (FDC) of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF), based on weight, for 96 weeks.
Drug: Doravirine · Drug: 2 NRTIs · Drug: DOR/3TC/TDF
Administered orally
Also known as: MK-1439
Administered orally
Drug pages: Lamivudine · Tenofovir
Administered orally
Also known as: MK-1439A
Area Under the Concentration-Time Curve (AUC) From 0 to 24 Hours Postdose (AUC0-24hr) of Doravirine (DOR) Following Once-Daily Dosing in Plasma at Steady-State
Per protocol, intensive pharmacokinetic (PK) sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine AUC0-24hr.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
Maximum Concentration (Cmax) of DOR Following Once-Daily Dosing in Plasma at Steady-State
Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Cmax.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
Concentration at 24 Hours (C24) of DOR Following Once-Daily Dosing in Plasma at Steady-State
Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine C24.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
Time to Maximum Concentration (Tmax) of DOR Following Once-Daily Dosing in Plasma at Steady-State
Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Tmax.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
AUC From 0 to 12 Hours Postdose (AUC0-12hr) of DOR Following Twice-Daily Dosing in Plasma at Steady-State
Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine AUC0-12hr.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
Cmax of DOR Following Twice-Daily Dosing in Plasma at Steady-State
Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine Cmax.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
Concentration at 12 Hours (C12) of DOR Following Twice-Daily Dosing in Plasma at Steady-State
Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine C12.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
Tmax of DOR Following Twice-Daily Dosing in Plasma at Steady-State
Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine Tmax.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
Percentage of Participants With ≥1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.
Time frame: Up to 24 weeks
Percentage of Participants With a Grade 3 or 4 AE
Grade 3 or 4 AEs are "severe symptoms that cause inability to perform usual social and functional activities with intervention or hospitalization indicated" (Grade 3), or "potentially life-threatening events" (Grade 4).
Time frame: Up to 24 weeks
Percentage of Participants With Events of Death
The percentage of participants with events of death at Week 24 will be reported.
Time frame: Up to 24 weeks
Percentage of Participants Discontinuing From Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.
Time frame: Up to 24 weeks
Percentage of Participants Discontinuing From Study Intervention Due to a Drug-Related AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered to be related to the study interventions.
Time frame: Up to 24 weeks
Plasma Concentration of DOR
Per protocol, sparse PK sampling includes up to 2 blood samples collected at multiple visits up to 24 weeks.
Time frame: Sparse pharmacokinetic sampling: at designated timepoints up to 24 weeks
Plasma Concentration of Lamivudine (3TC) Following Once-Daily Dosing of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) as an Age-Appropriate Fixed-Dose Combination (FDC)
Per protocol, sparse PK sampling includes up to 2 blood samples collected at multiple visits up to 24 weeks.
Time frame: Sparse pharmacokinetic sampling: at designated timepoints up to 24 weeks
Plasma Concentration of Tenofovir (TFV) Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC
Per protocol, sparse PK sampling includes up to 2 blood samples collected at multiple visits up to 24 weeks.
Time frame: Sparse pharmacokinetic sampling: at designated timepoints up to 24 weeks
AUC0-24hr of 3TC Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC
Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine AUC0-24hr of 3TC.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
AUC0-24hr of TFV Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC
Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine AUC0-24hr of TFV.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
Cmax of 3TC Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC
Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Cmax of 3TC.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
Cmax of TFV Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC
Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Cmax of TFV.
Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
Percentage of Participants With ≥1 AE at Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.
Time frame: Up to 48 weeks
Percentage of Participants With ≥1 AE at Week 96
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.
Time frame: Up to 96 weeks
Percentage of Participants With Grade 3 or 4 AE at Week 48
Grade 3 or 4 AEs are "severe symptoms that cause inability to perform usual social and functional activities with intervention or hospitalization indicated" (Grade 3), or "potentially life-threatening events" (Grade 4).
Time frame: Up to 48 weeks
Percentage of Participants With Grade 3 or 4 AE at Week 96
Grade 3 or 4 AEs are "severe symptoms that cause inability to perform usual social and functional activities with intervention or hospitalization indicated" (Grade 3), or "potentially life-threatening events" (Grade 4).
Time frame: Up to 96 weeks
Percentage of Participants With Events of Death at Week 48
The percentage of participants with events of death at Week 48 will be reported.
Time frame: Up to 48 weeks
Percentage of Participants With Events of Death at Week 96
The percentage of participants with events of death at Week 96 will be reported.
Time frame: Up to 96 weeks
Percentage of Participants Discontinuing From Study Intervention Due to AE at Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.
Time frame: Up to 48 weeks
Percentage of Participants Discontinuing from Study Intervention Due to AE at Week 96
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.
Time frame: Up to 96 weeks
Percentage of Participants Discontinuing From Study Intervention Due to Drug-Related AE at Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered to be related to the study interventions.
Time frame: Up to 48 weeks
Percentage of Participants Discontinuing From Study Intervention Due to Drug-Related AE at Week 96
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered to be related to the study interventions.
Time frame: Up to 96 weeks
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL at Week 24
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time polymerase chain reaction (PCR) assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 24 weeks
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 48 weeks
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 96 weeks
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 24
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 24 weeks
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 48 weeks
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 96 weeks
Percentage of Participants With HIV-1 RNA ≥50 copies/mL at Week 24
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 24 weeks
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 48
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 48 weeks
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Up to 96 weeks
Percentage of Participants With Log10 Drop in Plasma HIV-1 RNA From Baseline at Week 24
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants With Log10 Drop in Plasma HIV-1 RNA From Baseline at Week 48
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Baseline (Day 1) and Week 48
Percentage of Participants With Log10 Drop in Plasma HIV-1 RNA From Baseline at Week 96
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.
Time frame: Baseline (Day 1) and Week 96
Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 24
CD4+ T-cell counts will be performed at the central laboratory.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in CD4+ T-Cell Counts at Week 48
CD4+ T-cell counts will be performed at the central laboratory.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in CD4+ T-Cell Counts at Week 96
CD4+ T-cell counts will be performed at the central laboratory.
Time frame: Baseline (Day 1) and Week 96
Viral Resistance-Associated Substitutions (RASs) to DOR or Other Treatment Components
The presence of viral RASs to DOR or other treatment components will be monitored for up to 96 weeks.
Time frame: Up to 96 weeks
Percentage of Participants Adhering to DOR or to the FDC of DOR/3TC/TDF
Adherence to DOR or to the FDC of DOR/3TC/TDF will be monitored for up to 96 weeks.
Time frame: Up to 96 weeks
Assessment of Palatability/Acceptability of Oral Pellets/Granules of DOR or the FDC of DOR/3TC/TDF
Palatability/acceptability will be based on scores on the 5-point facial hedonic scale (FHS). FHS scores will be tabulated and summarized by mean and standard deviation (SD), on Day 28. The highest possible FHS score is 5, with higher scores indicative of greater palatability.
Time frame: Day 28
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Feb 2021 (actual). Primary completion is estimated for Nov 2028, 93 months after the start.
Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 93 months is above that.
Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Lamivudine · Tenofovir
Acquired Immunodeficiency Syndrome →